Teva calls on SCOTUS to take up battle over 'skinny' generic drug labels
Teva Pharmaceuticals this week called on the US Supreme Court to protect a longstanding precedent that allows generic drug companies to carve out and market certain indications for a patented reference product — known as a “skinny” label” — which have fallen in limbo thanks to a Federal Circuit court decision last summer.
“A divided panel of the Federal Circuit has blown a hole in the carefully calibrated regime governing the modern prescription-drug marketplace. The result is to allow a narrow patent on one way of using a drug to completely block any generic competition, potentially for years — precisely the opposite of what Congress prescribed,” Teva wrote in urging SCOTUS to take up the case.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.